Skip to main content
SpringerLink
Log in

Hochdosis-Chemotherapie des Mammacarcinoms

  • Chapter
Mammacarcinom

Part of the book series: Onkologie heute ((ONKOLOGIE))

  • 22 Accesses

Zusammenfassung

In Europa erkrankt ca. jede neunte Frau an einem Mammacarcinom. 1996 traten ca. 42.000 Neuerkrankungen in der Bundesrepublik Deutschland auf. Davon wurden etwa 25% der Patientinnen in einem lokal fortgeschrittenen Stadium (high-risk) und etwa 14% im metastasierten Stadium diagnostiziert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 29.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 39.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  1. Antman KH, Rowlings PA, Vaughan WP, Peltz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy HK, Klein JP, Lazarus HM, McCarthy PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM (1997) High-dose chemotherapy with autologous hema-topoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870–1879.

    PubMed  CAS  Google Scholar 

  2. Ayash LJ, Wheeler C, Fairclough D, Schwartz G, Reich E, Warren D, Schnipper L, Antman K, Frei 3rd E, Elias A (1995) Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13: 2043–2049.

    PubMed  CAS  Google Scholar 

  3. Bastholt L, Dalmark M, Gjedde SB, Pfeiffer P, Pedersen D, Sandberg E, Kjaer M, Mouridsen HAT, Rose C, Nielsen OS, Jakobsen P, Bentzen SM (1996) Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer. A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer group. J Clin Oncol 14: 1146–1155.

    PubMed  CAS  Google Scholar 

  4. Bearman SI, Overmoyer BA, Bolwell BJ, Taylor CW, Shpall EJ, Cagnoni PJ, Mechling BE, Ronk B, Baron AE, Purdy MH, Ross M, Jones RB (1997) High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4–9 involved axillary lymph nodes. Bone Marrow Transplant 20: 931–937.

    Article  PubMed  CAS  Google Scholar 

  5. Bezwoda W, Dansey R, Seyman C (1982) First line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 46: 836–839.

    Google Scholar 

  6. Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13: 2483–2489.

    PubMed  CAS  Google Scholar 

  7. Bezwoda WR (1997) Toward more active chemotherapy regimes: High-dose chemotherapy in the treatment of metastatic breast cancer. The Breast Journal 3 (Suppl.): 69–76.

    Google Scholar 

  8. Bitran JD, Samuels B, Klein L, Hanauer S, Johnson L, Martinec J, Harris E, Kempler J, White W (1996) Tandem high-dose chemotherapy supported by hematopoietic progenitor cell yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 17: 157–162.

    PubMed  CAS  Google Scholar 

  9. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15.

    Article  PubMed  CAS  Google Scholar 

  10. Bonadonna G, Zambetti M, Valagussa P (1995) Sequential or alternating doxorubicin and CMF regims in breast cancer with more than three positive nodes. Ten year results. JAMA 273: 542–547.

    Article  PubMed  CAS  Google Scholar 

  11. Broun ER, Sridhara R, Sledge GW, Loesch D, Kneebone PH, Hanna N, Hromas R, Cornetta K, Einhorn LH (1995) Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13: 2050–2055.

    PubMed  CAS  Google Scholar 

  12. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN (1989) Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12: 123–128.

    Article  PubMed  CAS  Google Scholar 

  13. Clark G, Sledge GW, Osborne CK, McGuire WL (1987) Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients. J Clin Oncol 5: 55–61.

    PubMed  CAS  Google Scholar 

  14. Dunphy FR, Spitzer G, Fornoff JE, Yau JC, Huan SD, Dicke KA, Buzdar AU, Hortobagyi GN (1994) Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 7: 2157–2167.

    Article  Google Scholar 

  15. Fields KK, Elfenbein GJ, Lazarus HM, Cooper BW, Perkins JB, Creger RJ, Ballester OF, Hiemenz JH, Janssen WE, Zorsky PE (1995) Maximum tolerated doses of ifos-famide, carboplatin, and etoposide given over six days followed by autologous stem-cell rescue: Toxicity profile. J Clin Oncol 13: 323–332.

    PubMed  CAS  Google Scholar 

  16. Fisher E, Sass R, Fisher B (1984) Pathologic findings form the national surgical adjuvant project for breast cancers (protocol no. 4). Cancer 53: 712–723.

    Article  PubMed  CAS  Google Scholar 

  17. Frei E, Antman K, Teicher B, Eder P, Schnipper L (1989) Bone marrow autotransplantation for solid tumors — Prospects. J Clin Oncol 7: 515–526.

    PubMed  Google Scholar 

  18. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, Hitt R, Hornedo R, Cortes-Funes H (1997) Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer. J Clin Oncol 15: 3178–3184.

    PubMed  CAS  Google Scholar 

  19. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, Salvadori B, Luini A, Greco M, Zucali R, Rilke F, Zambetti M, Valagussa P, Bonadonna G (1997) Efficacy, Toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 15: 2312–2321.

    PubMed  CAS  Google Scholar 

  20. Gisselbrecht C, Extra JM, Lotz JP, Devaux Y, Janvier M, Peny AM, Guillevin L, Bremond D, Delain M, Herbrecht R, Lepage E, Maraninchi D (1996) Cyclophos-phamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 18: 857–863.

    PubMed  CAS  Google Scholar 

  21. Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS (1994) Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. J Natl Cancer Inst 86: 975–982.

    Article  PubMed  CAS  Google Scholar 

  22. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197–2205.

    PubMed  CAS  Google Scholar 

  23. Hoogstratten B, George S, Samal B (1976) Combination chemotherapy and adriamy-cin in patients with advanced breast cancer. Cancer 38:13–20.

    Article  Google Scholar 

  24. Hortobagyi GN, Bodey GP, Buzdar AU, Frye D, Legha SS, Malik R, et al. (1987) Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5: 354–364.

    PubMed  CAS  Google Scholar 

  25. Hortobagyi GN, Buzdar AU, Champlin R, Gajewski J, Holmes FA, Booser D, Valero V, Theriault RL (1998) Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC) — A randomized trial. Proc ASCO 17: A471.

    Google Scholar 

  26. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy in metastatic breast cancer. J Clin Oncol 2: 1281–1288.

    PubMed  CAS  Google Scholar 

  27. Jones SE, Moon TE, Bonadonna G, Valagussa P, Rivkin S, Buzdar A, Montague E, Powles T (1987) Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Am J Clin Oncol (CCT) 10: 387–395.

    Article  CAS  Google Scholar 

  28. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE (1991) High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83: 920–926.

    Article  PubMed  CAS  Google Scholar 

  29. Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS (1992) Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 90: 3294–3298.

    Article  Google Scholar 

  30. Lichtman SM, Budman D, Bosworth S, Allen S, Schulman P, Weiselberg L, Weiss R, Lehrman D, Vinciguerra V (1991) Adjuvant therapy of stage II breast cancer treated with CMFVP, radiation therapy and VATH following lumpectomy. Am J Clin Oncol 14: 317–321.

    Article  PubMed  CAS  Google Scholar 

  31. Manz M, Brümmendorf TH, Scheding S, Brugger W, Kanz L (1998) Phase I/II study of double high-dose chemotherapy with PBPC-transplantation after docetaxel/ad-riamycin induction in patients with primary stage III/IV breast cancer. Proc ASCO 17: A602.

    Google Scholar 

  32. Nemoto T, Vana J, Bedawani RN, Baker HW, McGregor FH, Murphy GP (1980) Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 45: 2917–2924.

    Article  PubMed  CAS  Google Scholar 

  33. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132–1143.

    PubMed  CAS  Google Scholar 

  34. Peters WP, Berry D, Vredenburgh JJ, Hussein A, Rubin P, Elkordy M, Ross M, Henderson IC, Budman D, Norton L, Weiss R, Hurd D (1995) Five year follow-up of high dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving greater than or equal to 10 axillary lymph nodes. Proc ASCO: A933.

    Google Scholar 

  35. Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkordy M, Rubin P, Ross M, Berry D (1996) A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular supports (ABMT) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc ASCO 15: A149.

    Google Scholar 

  36. Rahman ZU, Frye DK, Buzdar AU, Smith TL, Asmar L, Champlin RE, Hortobagyi GN (1998) Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 15: 3171–3177.

    Google Scholar 

  37. Ravdin PM, Callander NS (1998) Correspondence: Registry results and high-dose therapy. J Clin Oncol 16: 387–388.

    PubMed  CAS  Google Scholar 

  38. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CCE, Peterse JL, Borger JH, Nooijen WJ, Bakx R, Dalesio O, Rutgers E (1998) Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymphe node involvement. Lancet 352: 515–521.

    Article  PubMed  CAS  Google Scholar 

  39. Rosti G, Ferrante P, Chauvin F, Buclon M, Abdelbost Z, Ruiz de Elvira MC, Singrelin P, Chesnel V (1997) EBMT: Solid tumor working party and registry. 1997 Report: 41–53.

    Google Scholar 

  40. Somlo G, Dordshow JH, Forman S, Leong LA, Margolin KA, Morgan Jr RJ, Raschko JW, Akman SA, Ahn C, Nagasawa S, Harrison J (1994) High-dose doxorubicin, eto-poside, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team. Cancer 73:1678–1685.

    Article  PubMed  CAS  Google Scholar 

  41. Teicher BA, Ara G, Deyses SR, Herbst RS, Frei 3rd E (1998) Acute in vivo resistance in high-dose therapy. Clin Cancer Res 4: 483–491.

    PubMed  CAS  Google Scholar 

  42. Tomiak E, Piccart M, Mignolet F, Sahmoud T, Paridaens R, Nooy M, Beex L, Fentiman IS, Muller A, van der Schueren E, Rubens RD (1996) Characterisation of complete responders to combination chemotherapy for advanced breast cancer: A retrospective EORTC breast group study. Europ J Cancer 32A: 1876–1887.

    Article  CAS  Google Scholar 

  43. Tormey DC, Weinberg VE, Holland JF, et al. (1983) A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1: 138–145.

    PubMed  CAS  Google Scholar 

  44. Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy: Analysis of 716 consecutive patients. Cancer 41: 1170–1178.

    Article  PubMed  CAS  Google Scholar 

  45. Williams SF, Mick R, Desser R, Golick J, Beschorner J, Bitran JD (1989) High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer. J Clin Oncol 7: 1824–1830.

    PubMed  CAS  Google Scholar 

  46. Williams SF, Gilewski T, Mick R, Bitran JD (1992) High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 10: 1743–1747.

    PubMed  CAS  Google Scholar 

  47. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow AC, Frei 3rd E, Henderson IC (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330: 1253–1259.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik II, Universität Tübingen, Otfried-Müller-Straße 10, D-72076, Tübingen, Deutschland

    Dr. med. Markus Manz, PD Dr. med. Wolfram Brugger & Prof. Dr. med. Lothar Kanz

Authors
  1. Dr. med. Markus Manz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. PD Dr. med. Wolfram Brugger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. Lothar Kanz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinische Abteilung für Onkologie, Univ.-Klinik für Innere Medizin I Allgemeines Krankenhaus, Wien, Österreich

    Christoph Zielinski

  2. Klinische Abteilung für Allgemeinchirurgie, Univ.-Klinik für Chirurgie Allgemeines Krankenhaus, Wien, Österreich

    Raimund Jakesz

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Wien

About this chapter

Cite this chapter

Manz, M., Brugger, W., Kanz, L. (1999). Hochdosis-Chemotherapie des Mammacarcinoms. In: Zielinski, C., Jakesz, R. (eds) Mammacarcinom. Onkologie heute. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6402-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6402-0_9

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83168-7

  • Online ISBN: 978-3-7091-6402-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation